• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Fresh Tracks Therapeutics Announced Today Receipt Of Notice From Nasdaq Stating That Company's Common Stock Will Be Suspended From Trading On Nasdaq Capital Market At The Open Of Business On Dec. 19, 2023

    12/18/23 8:16:59 AM ET
    $FRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $FRTX alert in real time by email

    Fresh Tracks intends to reconvene its special meeting of stockholders on December 27, 2023 and encourages all stockholders of record on October 17, 2023 who have not yet voted to submit their proxy by 11:59 p.m. Eastern Time on December 26, 2023. If Fresh Tracks' stockholders do not approve Proposal 1, Approval of the Liquidation and Dissolution of the Company and the Plan of Liquidation and Dissolution (the "Plan of Dissolution"), which, if approved, will authorize the Company and the Board of Directors to Liquidate and Dissolve the Company in accordance with the Plan of Dissolution, Fresh Tracks intends to seek judicial dissolution, which is likely to be costly and time-consuming and would reduce the amount of cash distributable to Fresh Tracks' stockholders associated with the Company's dissolution.

    Get the next $FRTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FRTX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FRTX
    SEC Filings

    View All

    SEC Form 15-12G filed by Fresh Tracks Therapeutics Inc.

    15-12G - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

    3/18/24 5:05:32 PM ET
    $FRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Fresh Tracks Therapeutics Inc.

    10-K - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

    3/15/24 4:09:01 PM ET
    $FRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fresh Tracks Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

    3/7/24 8:44:19 AM ET
    $FRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FRTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fresh Tracks Therapeutics Announces Dissolution, Initial Cash Distribution and Termination of Trading on the OTC Pink Market

    BOULDER, Colo., Feb. 25, 2025 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or the "Company") announced today an update on its previously announced, planned dissolution and its process for distributing cash to its stockholders. Fresh Tracks plans on filing a Certificate of Dissolution with the Delaware Secretary of State, with dissolution effective February 28, 2025. As previously disclosed, on January 15, 2025, the Court of Chancery of the State of Delaware appointed Albert N. Marchio II as the custodian of the Company (the "Custodian"). In connection with the dissolution, the Custodian has authorized an initial distribution of $0.96 per share to holders, as of

    2/25/25 4:05:00 PM ET
    $FRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    /C O R R E C T I O N -- Fresh Tracks Therapeutics, Inc./

    In the news release, Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution, issued 27-Jan-2025 by Fresh Tracks Therapeutics, Inc. over PR Newswire, we are advised by the company that the reference to "...first quarter of 2024" at the end of the first paragraph was incorrectly stated and should read "...first quarter of 2025". The complete, corrected release follows: Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution BOULDER, Colo., Jan. 27, 2025 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or "the Company") announced today that the Court of Chancery of the State of Delaware ("the Court") has g

    1/27/25 4:05:00 PM ET
    $FRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution

    BOULDER, Colo., Jan. 27, 2025 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or "the Company") announced today that the Court of Chancery of the State of Delaware ("the Court") has granted the consent judgment agreed to by the Company in the case of David R. McAvoy versus Fresh Tracks, as a result of which the Court has appointed Albert N. Marchio II, Chief Executive Officer and Chief Financial Officer of Fresh Tracks, as the custodian of Fresh Tracks pursuant to 8 Del. C. § 226 with a directive to dissolve the Company and wind up its affairs. Fresh Tracks currently anticipates it will complete the dissolution and make a distribution of between $0.95 and $0.98 per

    1/27/25 4:05:00 PM ET
    $FRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FRTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Exploration Capital, Llc bought $381,170 worth of shares (405,500 units at $0.94) (SEC Form 4)

    4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

    6/11/24 9:37:53 PM ET
    $FRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Exploration Capital, Llc bought $9,580 worth of shares (10,434 units at $0.92) (SEC Form 4)

    4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

    5/31/24 5:29:19 PM ET
    $FRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Exploration Capital, Llc bought $20,821 worth of shares (22,889 units at $0.91) (SEC Form 4)

    4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

    5/23/24 5:29:14 PM ET
    $FRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Exploration Capital, Llc bought $381,170 worth of shares (405,500 units at $0.94) (SEC Form 4)

    4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

    6/11/24 9:37:53 PM ET
    $FRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Exploration Capital, Llc bought $9,580 worth of shares (10,434 units at $0.92) (SEC Form 4)

    4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

    5/31/24 5:29:19 PM ET
    $FRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Exploration Capital, Llc bought $20,821 worth of shares (22,889 units at $0.91) (SEC Form 4)

    4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

    5/23/24 5:29:14 PM ET
    $FRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FRTX
    Leadership Updates

    Live Leadership Updates

    View All

    /C O R R E C T I O N -- Fresh Tracks Therapeutics, Inc./

    In the news release, Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution, issued 27-Jan-2025 by Fresh Tracks Therapeutics, Inc. over PR Newswire, we are advised by the company that the reference to "...first quarter of 2024" at the end of the first paragraph was incorrectly stated and should read "...first quarter of 2025". The complete, corrected release follows: Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution BOULDER, Colo., Jan. 27, 2025 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or "the Company") announced today that the Court of Chancery of the State of Delaware ("the Court") has g

    1/27/25 4:05:00 PM ET
    $FRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution

    BOULDER, Colo., Jan. 27, 2025 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or "the Company") announced today that the Court of Chancery of the State of Delaware ("the Court") has granted the consent judgment agreed to by the Company in the case of David R. McAvoy versus Fresh Tracks, as a result of which the Court has appointed Albert N. Marchio II, Chief Executive Officer and Chief Financial Officer of Fresh Tracks, as the custodian of Fresh Tracks pursuant to 8 Del. C. § 226 with a directive to dissolve the Company and wind up its affairs. Fresh Tracks currently anticipates it will complete the dissolution and make a distribution of between $0.95 and $0.98 per

    1/27/25 4:05:00 PM ET
    $FRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fresh Tracks Therapeutics Announces Delaware Petition Filed Seeking Appointment of Custodian for Eventual Dissolution of Company

    BOULDER, Colo., June 17, 2024 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or the "Company") announced today that it has filed an Answer (the "Answer") to a Verified Petition for Appointment of a Custodian Pursuant to 8 Del. C. § 226 (the "Delaware Petition") that was filed with the Court of Chancery of the State of Delaware (the "Court") on May 17, 2024 by a stockholder and former General Counsel, Chief Compliance Officer, and Secretary of the Company, David R. McAvoy (the "Petitioner"). The Delaware Petition, to which the Answer outlines the Company is in overall agreement with, specifically requests that the Court issue an order appointing Albert N. Ma

    6/17/24 4:05:00 PM ET
    $FRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FRTX
    Financials

    Live finance-specific insights

    View All

    Fresh Tracks Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

    Reported positive topline results from SAD and MAD parts of Phase 1 study of lead DYRK1A inhibitor FRTX-02 in March 2023 Ongoing evaluation of strategic options to further develop FRTX-02 and maximize shareholder value Strengthened balance sheet with aggregate net proceeds of $6.6 million raised under an ATM program in March 2023 BOULDER, Colo., May 10, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (the "Company" or "Fresh Tracks") (NASDAQ:FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today

    5/10/23 4:01:00 PM ET
    $FRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fresh Tracks Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

    Positive topline results from single and multiple ascending dose parts of the Phase 1 study of FRTX-02 support its continued development as a potential first-in-class, once-daily oral treatment for atopic dermatitis and/or other autoimmune diseases Continuing to evaluate strategic options to further develop FRTX-02 and maximize shareholder value Raised aggregate net proceeds of $6.6 million under ATM program in March 2023 BOULDER, Colo., March 30, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (the "Company" or "Fresh Tracks") (NASDAQ:FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription the

    3/30/23 4:01:00 PM ET
    $FRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Fresh Tracks Therapeutics Inc.

    SC 13D - Fresh Tracks Therapeutics, Inc. (0000819050) (Subject)

    5/8/24 4:01:47 PM ET
    $FRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Fresh Tracks Therapeutics Inc. (Amendment)

    SC 13G/A - Fresh Tracks Therapeutics, Inc. (0000819050) (Subject)

    1/17/24 8:37:18 PM ET
    $FRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Fresh Tracks Therapeutics Inc. (Amendment)

    SC 13G/A - Fresh Tracks Therapeutics, Inc. (0000819050) (Subject)

    2/13/23 5:24:48 PM ET
    $FRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care